{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:17:34Z","timestamp":1791839854573,"version":"4.3.4"},"reference-count":35,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3542,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1368-5031.2005.00754.x","type":"journal-article","created":{"date-parts":[[2005,12,20]],"date-time":"2005-12-20T11:12:17Z","timestamp":1135077137000},"page":"85-92","source":"Crossref","is-referenced-by-count":49,"title":["Methylprednisolone aceponate* in eczema and other inflammatory skin disorders - a clinical update"],"prefix":"10.1155","volume":"60","author":[{"given":"T.","family":"Ruzicka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2005,12,20]]},"reference":[{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2133.1984.tb07467.x","article-title":"The dermatology out-patient service. a study of out-patient referrals in a Scottish population","volume":"110","author":"Benton","year":"1984","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0190-9622(94)70004-4","article-title":"The prevalence of childhood atopic eczema in a general population","volume":"30","author":"Kay","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2340\/0001555577052053","article-title":"Prevalence of infantile and early childhood eczema in a Japanese population: comparison with the disease frequency examined 20 years ago","volume":"77","author":"Sugiura","year":"1997","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/003693309804300607","article-title":"Is the increase in asthma prevalence occurring in children without a family history of atopy?","volume":"43","author":"Christie","year":"1998","journal-title":"Scott Med J"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB5|cit5","first-page":"247","article-title":"Methylprednisolone aceponate (Advantan\u00ae) - an effective topical corticoid therapy with few side effects","volume":"3","author":"Zaumseil","year":"1992","journal-title":"Jahrbuch der Dermatologie"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0190-9622(09)80276-4","article-title":"Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers","volume":"28","author":"Kecsk\u00e9s","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00754.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/09546639209092768","article-title":"Clinical experience with methylprednisolone ace-ponate (MPA) in eczema","volume":"3","author":"Fritsch","year":"1992","journal-title":"J Dermatolog Treat"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00754.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1111\/j.1468-3083.1994.tb01063.x","article-title":"Clinical comparison of methylprednisolone aceponate and prednicarbate in chronic eczema","volume":"3","author":"Albrecht","year":"1994","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB9|cit9","first-page":":","article-title":"New developments in corticosteroid research","volume":"1 (Suppl. 3)","author":"Toepert","year":"1990","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF03259059","article-title":"Methylprednisolone aceponate. A review of its pharmacological properties and therapeutic potential in the topical treatment of eczema","volume":"3","author":"Haria","year":"1995","journal-title":"Clin Immunother"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00754.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1468-3083.1994.tb01060.x","article-title":"Pharmacokinetics and bioactivation of MPA","volume":"3","author":"T\u00e4uber","year":"1994","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00754.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1468-3083.1994.tb01061.x","article-title":"Preclinical evaluation of a new topical corticosteroid methylprednisolone aceponate","volume":"3","author":"Zentl","year":"1994","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00003495-198019020-00004","article-title":"Topical corticosteroids: clinical pharmacology and therapeutic use","volume":"19","author":"Miller","year":"1980","journal-title":"Drugs"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB14|cit14","first-page":"144","article-title":"Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers","volume":"43","author":"Kecsk\u00e9s","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00002018-199614060-00003","article-title":"Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept","volume":"14","author":"Sch\u00e4fer-Korting","year":"1996","journal-title":"Drug Saf"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB16|cit16","first-page":"281","article-title":"Experience with methylprednisolone aceponate (MPA) in patients suffering from acute and chronic eczema. Results of a large observational study","volume":"73","author":"Mensing","year":"1998","journal-title":"Z Hautkr"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00754.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1111\/j.1468-3083.1994.tb01058.x","article-title":"Skin atrophogenic potential of methylprednisolone acetate (MPA)","volume":"3","author":"Ortonne","year":"1994","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2165\/00002018-199410050-00005","article-title":"Topical corticosteroids and unwanted local effects. Improving the benefit\/risk ratio","volume":"10","author":"Mori","year":"1994","journal-title":"Drug Saf"},{"issue":"Suppl. 1","key":"10.1111\/j.1368-5031.2005.00754.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1111\/j.1468-3083.1994.tb01059.x","article-title":"Long-term treatment with 6-alpha methylprednisolone aceponate","volume":"3","author":"Haneke","year":"1994","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Part 1","key":"10.1111\/j.1368-5031.2005.00754.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0190-9622(09)80275-2","article-title":"Local tolerability of topically applied methylprednisolone aceponate","volume":"28","author":"Kecsk\u00e9s","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/0190-9622(93)70224-H","article-title":"Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity","volume":"29","author":"Kecsk\u00e9s","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 2","key":"10.1111\/j.1368-5031.2005.00754.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/09546639209092770","article-title":"Methylprednisolone aceponate (MPA) - use and clinical experience in children","volume":"3","author":"Rampini","year":"1992","journal-title":"J Dermatol Treat"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB23|cit23","first-page":"399","article-title":"The milk formulation in topical corticotherapy: outcomes in children with atopic dermatitis","volume":"XV","author":"Casano","year":"2002","journal-title":"Monografia de Dermatologia"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB24|cit24","first-page":"61","article-title":"The use of steroid Advantan (methylprednisolone aceponate) for management of allergodermatoses in children","volume":"3","author":"Korotky","year":"2000","journal-title":"Vestn Dermatol Venereol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB25|cit25","first-page":"8","article-title":"Die behandlung des atopischen ekzems (neurodermitis) im kindesalter mit 6-alpha-methylprednisoloneaceponat [in German]","volume":"44","author":"Soennichsen","year":"1996","journal-title":"Der Deutsche Dermatologe"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1439-0353.2002.02526.x","article-title":"Effectiveness and tolerability of methylprednisolone aceponate (Advantan\u00ae) in the treatment of eczematous disorders of the face","volume":"77","author":"Ruzicka","year":"2002","journal-title":"Z Hautkr"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB27|cit27","first-page":"317","article-title":"Efficacy and tolerability of methylprednisolone aceponate solution in eczematous disease of the hairy scalp","volume":"5","author":"Soennichsen","year":"1999","journal-title":"Derm"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2002.01033.x","article-title":"A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers","volume":"27","author":"Duteil","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2710.2000.00254.x","article-title":"Therapeutic strategies for psoriasis","volume":"25","author":"Ashcroft","year":"2000","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0300-2977(97)00081-8","article-title":"The management of psoriasis","volume":"52","author":"Van de Kerkhof","year":"1998","journal-title":"Neth J Med"},{"issue":"Suppl. 28","key":"10.1111\/j.1368-5031.2005.00754.x-BIB31|cit31","first-page":"S81","article-title":"Standard and innovative therapy of psoriasis","volume":"20","author":"Geilen","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB32|cit32","first-page":"4","article-title":"Topical therapy of psoriasis vulgaris in children and young adults","volume":"18","author":"Wozel","year":"1996","journal-title":"Soz Padiatr Kinderarztl Prax"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB33|cit33","first-page":"49","article-title":"Use of different pharmaceutical forms of Advantan (methylprednisolone aceponate) for combined treatment of patients with psoriasis [in Russian]","volume":"2","author":"Filimonkova","year":"2002","journal-title":"Vestn Dermatol Venereol"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB34|cit34","first-page":"240","article-title":"The clinical assessment of calcipotriol and methylprednisolone aceponate ointments in treatment of psoriasis vulgaris [in Russian]","volume":"17","author":"Tarim","year":"2000","journal-title":"Ondokuz Mayis Universitesi Tip Dergisi"},{"key":"10.1111\/j.1368-5031.2005.00754.x-BIB35|cit35","unstructured":"Luger TA."}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1368-5031.2005.00754.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1368-5031.2005.00754.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T20:49:53Z","timestamp":1706820593000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1368-5031.2005.00754.x"}},"subtitle":["MPA IN ECZEMA AND OTHER INFLAMMATORY SKIN DISORDERS"],"short-title":[],"issued":{"date-parts":[[2005,12,20]]},"references-count":35,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1111\/j.1368-5031.2005.00754.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12,20]]}}}